Abstract 460P
Background
Cancer diagnosis and treatment can give rise to psychological challenges for patients. Amidst the adversity, there exists the potential for post-traumatic growth (PTG), a phenomenon characterized by positive psychological changes and personal development following traumatic experiences. Group-based interventions have emerged as a promising avenue for fostering PTG among individuals with cancer. This systematic review aims to assess the group-based interventions designed to facilitate PTG in cancer patients.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used were group-based intervention, group therapy, PTG, positive psychological change, and cancer. Publications were limited to English manuscripts published in the last 10 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review encompassed a selection of 12 studies, with 970 individuals aged above 18 years. The sampled patients displayed wide cancer types, including breast, gynaecologic, hematologic, head and neck, gastrointestinal, urological, and lymphoma. Group therapies in this review were mindfulness-based psychotherapy, cognitive behavioural stress management, acceptance and commitment therapy, supportive and positive group therapy, art and relaxation response resiliency mind-body program, varied from 5-12 sessions. The primary assessment tool is Post-Traumatic Growth Inventory (PTGI). The findings suggest that group interventions contribute to the personal strength, positive affect, and sense of meaning in cancer-related trauma. While positive trends were observed, the magnitude of PTG outcomes varied, likely influenced by duration, composition, and participant readiness for growth.
Conclusions
To conclude, this systematic review assesses the potential of group-based interventions as resource in promoting PTG among cancer patients. Nevertheless, the variations in outcomes across studies emphasize the need for interventions, accounting for individual differences. This review contributes to our understanding of the relationship between group-based interventions and PTG among cancer patients, paving the way for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. G. William.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract